| Literature DB >> 26025053 |
A I Tsonis1, P Zisimopoulou2, K Lazaridis3, J Tzartos3, E Matsigkou3, V Zouvelou4, R Mantegazza5, C Antozzi5, F Andreetta5, A Evoli6, F Deymeer7, G Saruhan-Direskeneli7, H Durmus7, T Brenner8, A Vaknin8, S Berrih-Aknin9, A Behin9, T Sharshar10, M De Baets11, M Losen11, P Martinez-Martinez11, K A Kleopa12, E Zamba-Papanicolaou12, T Kyriakides12, A Kostera-Pruszczyk13, P Szczudlik13, B Szyluk13, D Lavrnic14, I Basta14, S Peric14, C Tallaksen15, A Maniaol16, C Casasnovas Pons17, J Pitha18, M Jakubíkova18, F Hanisch19, S J Tzartos20.
Abstract
Seronegative myasthenia gravis (MG) presents a serious gap in MG diagnosis and understanding. We applied a cell based assay (CBA) for the detection of muscle specific kinase (MuSK) antibodies undetectable by radioimmunoassay. We tested 633 triple-seronegative MG patients' sera from 13 countries, detecting 13% as positive. MuSK antibodies were found, at significantly lower frequencies, in 1.9% of healthy controls and 5.1% of other neuroimmune disease patients, including multiple sclerosis and neuromyelitis optica. The clinical data of the newly diagnosed MuSK-MG patients are presented. 27% of ocular seronegative patients were MuSK antibody positive. Moreover, 23% had thymic hyperplasia suggesting that thymic abnormalities are more common than believed.Entities:
Keywords: Autoantibodies; Cell based assay; Diagnosis; MuSK; Myasthenia gravis
Mesh：
Substances：
Year: 2015 PMID： 26025053 DOI： 10.1016/j.jneuroim.2015.04.015
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478